Market Moves
NeuroPace beats Q1, raises guidance, and posts 77% seizure reduction in expanded-indication trial
NeuroPace reported Q1 2026 RNS System revenue of $21.7 million (up 19.5% year-on-year), raised full-year guidance to $99-101 million, and detailed 18-month NAUTILUS trial data showing a 77% median reduction in generalised tonic-clonic seizures. FDA paused the 180-day clock on the expanded-indication review; midyear determination still anticipated.